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Abstract
Background: The prevalence and role of human papillomavirus (HPV) in the aetiology of oesophageal squamous cell
carcinoma is uncertain. Based on the presence of HPV in the oral cavity and its causal association with squamous cell
carcinoma of the oropharynx, we hypothesised that HPV is more strongly associated with proximal than distal oesophageal
squamous cell carcinoma.
Methods: A population-based study comparing HPV infection in relation to tumour site in patients diagnosed with
oesophageal squamous cell carcinomas in the Stockholm County in 1999–2006. Multiplex polymerase chain reaction
genotyping (PCR) with Luminex was conducted on pre-treatment endoscopic biopsies to identify type specify HPV.
Carcinogenic activity of HPV was assessed by p16INK4a expression. Multivariable logistic regression was used to calculate
odds ratios and 95% confidence intervals.
Results: Among 204 patients, 20 (10%) had tumours harbouring HPV DNA, almost all (90%) of HPV high-risk type, mainly
HPV16. Tumours containing HPV were not overrepresented in the upper compared to the middle or lower third of the
oesophagus (odds ratio 0.6, 95% confidence interval 0.2–1.9). P16INK4a expression was similarly common (24% and 16%) in
the HPV-positive and HPV-negative groups.
Conclusion: This study found a limited presence of HPV in oesophageal squamous cell carcinoma of uncertain oncogenic
relevance and did not demonstrate that HPV was more strongly associated with proximal than distal tumours.
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Introduction
The introduction of preventive vaccines against human
papillomavirus (HPV) has increased the incentive to clarify
possible causal links between HPV and non-cervical carcinomas,
for example oesophageal squamous cell carcinoma cancer.
Oesophageal cancer is the 8th most common type of cancer
and the 6th most common cause of death from cancer, globally,
[1] and the 5-year survival is only about 10% in Western
countries. [2] Therefore, preventive measures are highly
warranted, and HPV infection might be one such target. HPV
is causally linked with cervical cancer, [3,4,5] and has recently
also been established as a risk factor for oropharyngeal squamous
cell carcinoma. [6,7,8,9] An association between HPV and
oesophageal squamous cell carcinoma was initially suggested in
1982 when morphological similarities between HPV induced
lesions in the genital tract and oesophageal squamous cell
carcinomas were found. [10] Since then several studies have been
conducted, using varying or no control subjects and different
virus detection methods, producing conflicting results. The
frequency of HPV DNA in oesophageal squamous cell carcino-
mas shows a great diversity in frequency around the world, with
usually high HPV incidence in high-risk areas including China,
[11] although recently contradicted [12] while studies from North
America and Europe indicate a lower frequency (0–30%).
[13,14,15,16,17] It has also been reported that patients with
current or a history of HPV positive head and neck cancer also
have an increased risk of HPV related squamous cell cancer in
the oesophagus. [18] Because of the association of HPV with
oropharyngeal cancer, the presence of HPV in the oral cavity,
and the varying results in previous research, we hypothesised that
HPV would be associated with a more proximal than distal site in
oesophageal squamous cell carcinoma. The present study aimed
to test this hypothesis.
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Materials and Methods
Study design
This population-based study included patients diagnosed with
oesophageal squamous cell carcinoma in the Stockholm County in
Sweden during the period 1999 to 2006. The patients were
identified through the Swedish Cancer Register, a nationwide
register initiated in 1958 with a completeness of 96% for all
cancers [19] and 98% for oesophageal cancer. [20] Medical
records were examined to enable categorisation of patients into 3
groups depending on tumour localisation: upper (15–24 centime-
tres from the tooth line), middle (24–32 centimetres from the tooth
line), or lower (32–40 centimetres from the tooth line) third of the
oesophagus. Histologically confirmed paraffin embedded endo-
scopic biopsies from oesophageal squamous cell carcinomas,
obtained before treatment, were reviewed by one pathologist
(CL). To avoid detection bias, only endoscopic biopsies were
included. Surgical resection is more common in distal compared to
proximal oesophageal tumours, and analysis of resected tissue
could provide a better assessment of HPV infection, and the
detection of HPV between the locations of the tumours could be
biased if surgical specimens would have been included.
Detection of human papilloma virus
Detection of HPV in the tumour biopsies was conducted as
follows. Formalin-fixated paraffin embedded biopsies were sec-
tioned into 4615 mm slices on glass, and macro-dissected to make
sure that the section contained at least 70% tumour cells. To
minimise contamination, blanks were added after every 5th sample
and treated in the same way as regular samples during slicing and
micro-dissection. DNA extraction was performed using the High
Pure RNA Paraffin Kit (Roche’s) without DNAse. PCR was
performed by adding 10 ml of DNA sample and 40 ml of reaction
mixture, containing broad-spectrum GP5+/6+ primers (BGP5+/
BGP6+), to the Qiagen Multiplex PCR Master Mix (Qiagen,
Hilden, Germany) [21]. Amplification was made in 40 cycles, with
an annealing temperature of 38uC for 90 seconds. HPV genotyp-
ing was conducted with Luminex [22,23] together with a
Multimetrix kit (Heidelberg, Germany), analysing 24 HPV types,
including 15 HR types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 68, 73, 82), 3 putative HR types (26, 53, 66) and 6 LR types (6,
11, 42, 43, 44, 70) [24]. Hybridisation of PCR products (10 ml) and
Luminex beads (40 ml) together with the subsequent steps were
performed using standard methods. The samples were analysed
using a Luminex 100 analyser (BioRad Laboratories, Hercules,
USA) with the cut-off limits proposed by Multimetrix.
Detection of p16INK4a by immunohistochemistry
To assess biological activity of HPV in the tumours, p16INK4a, a
surrogate marker for HPV activity, [25,26] was measured with
immunohistochemistry. The biopsies were sectioned and stained
using the monoclonal antibody p16 INK4a (delusion 1:200, clone
JC8, Santa Cruz Biotechnology, INC) and a standard streptavidin-
biotin peroxidase method. One pathologist (EA) examined and
graded all samples according to predetermined conditions, and
samples were categorised as negative if no of the tumour cells were
staining for p16 INK4a, weakly and unspecifically stained if a
minority and ungrouped tumour cells were stained, and positive if
there was a homogeneous staining of a clear majority of the
tumour cells were stained for p16 INK4a. The slides showing weak
and unspecific staining were included in the p16 INK4a negative
category in the analysis.
Statistical analysis
Fisher’s exact test was used to identify predictors for HPV-
positive tumours. A p-value below 0.05 was considered statistically
significant. Unconditional logistic regression was used to calculate
relative risk between HPV infection and risk of various tumour
sites in the oesophagus, expressed as odds ratios (OR) with 95%
confidence intervals (CI). Using multivariable modelling, ORs
were adjusted for age (grouped into ,60, 60–70, or .70 years),
sex, and tumour differentiation (high, middle, or low). Any missing
data was grouped into a separate category in these analyses.
Ethics
The study was approved by the Regional Ethics Review Board
in Stockholm.
Results
Study participants
Among 348 new cases of oesophageal squamous cell carcinoma
in the Stockholm County between 1999 and 2006, 67 (19%) were
excluded because of; tumour misclassification (n = 3, 1%),
diagnosis based on autopsy results (n = 11, 3%), or failure to
identify any endoscopic biopsy (n = 53, 15%). Among 281 (81%)
eligible patients, 77 (27%) were classified as non-participants; 51
(18%) because of lack of tumour material and 26 (9%) because of
tumour material being unavailable. Finally, 204 patients (73%)
remained for the present study. Characteristics of the participants,
non-participants and excluded patients are presented in Table 1.
The distribution of sex, age and tumour location were similar
between these groups, except for more missing data regarding
tumour location in the excluded group (Table 1).
Table 1. Differences between included and excluded
patients.
Variable Participants
Non-participants/
excluded*
Number (%) Number (%)
Total 204 (59) 144 (41)
Sex
Men 127 (62) 94 (65)
Women 77 (38) 50 (35)
Age at diagnosis (years)
,60 37 (18) 23 (16)
60–70 76 (37) 52 (36)
.70 91 (45) 69 (48)
Tumour location#
Upper third 53 (26) 23 (16)
Middle third 64 (31) 45 (31)
Lower third 83 (41) 45 (31)
Unspecified 2 (1) 5 (4)
Missing 2 (1) 26 (18)
*Nonparticipants include low DNA level (n = 51, 18%) and unable to collect the
endoscopic biopsy (n = 26, 9%). Excluded participants include tumour
misclassification (n = 3, 1%), tumour detected at autopsy (n = 11, 3%) and
unavailable endoscopic material (n = 53, 15%).
#Tumour location was similar in the participants and non-participant/excluded
groups (p = 0.113, Fishers exact test) except for more missing in the non-
participant/excluded group p,0.001, Fishers exact test).
doi:10.1371/journal.pone.0046538.t001
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Detection of HPV and p16INK4a
Characteristics of patients with HPV-positive and HPV-
negative tumours are presented in Table 2. In total, 20 (10%)
tumours were positive for HPV DNA, of which 18 (90%)
harboured high-risk HPV types (16 (n = 13), 33 (n = 1), 45
(n = 1), 51 (n = 2), 52 (n = 1)1, 73 (n = 1), 82 (n = 1)1, 1 (5%)
putative high-risk type (66)1 and 1 (5%) low-risk type (42).
P16INK4a expression was evaluated in 17/20 (85%) HPV positive
cases (3 lacked any material left) and in 113 HPV negative cases
(6,5 HPV negative control per HPV positive case). The prevalence
of p16INK4a expression in the HPV-positive (24%) and HPV-
negative (16%) tumours was not statistically significantly different
(Table 2).
Association between HPV and tumour site
Patients with tumours containing HPV DNA did not have any
increased risk of having a tumour located in the upper third of the
oesophagus compared to a more distal site (adjusted OR 0.6, 95%
CI 0.2–1.9, Table 3). The comparison of upper/middle versus
lower tumour site rendered an adjusted OR of 2.1 (95% CI 0.7–
6.3, Table 3). The majority of the HPV-positive tumours were
rather located in the middle oesophagus (55), and the HPV-
negative tumours were more frequently found in the distal
oesophagus (42%), although no statistically significant differences
were observed.
Discussion
This study indicates a limited presence of human papillomavirus
(HPV) DNA in oesophageal squamous cell carcinoma in a
Swedish population, and does not provide support for the
hypothesis of an increased prevalence of squamous cell carcinomas
infected with HPV in the proximal compared to the distal
oesophagus. Furthermore, the p16INK4a data do not support a
carcinogenetic role in the oesophageal squamous cell cancers
harbouring high-risk HPV.
Strengths of the present study include its population-based
design, the high number of patients included compared to other
studies in the same area, the valid assessment of the exposure and
outcome, and the ability to adjust for potential confounding
factors. The use of oesophageal squamous cell carcinoma patients
as both case and control subjects ensured similar risk factor
profiles, such as for example smoking and alcohol use, and thus
reduced confounding. The use of endoscopic biopsies in all
participants circumvented biased detection of HPV infection
between tumour sites. The biopsies were taken prior to any
preoperative treatment, which ensured that the studied tumour
material was not affected by e.g. chemotherapy or radiotherapy.
Finally, the detection of HPV DNA using Luminex on PCR
product is an established method with a high sensitivity. [22]
Limitations include a low statistical power, which was largely
due to insufficient DNA material in some biopsies and a low
prevalence of HPV infection in the tumours. Furthermore, due to
the limited size of the tumour biopsies, we could not assay for HPV
E6 and E7 mRNA as marker for active HPV in tumour cells,
instead we analysed for p16 INK4a, which has previously been used
as a surrogate marker for HPV in cervical cancer [27] and HPV
activity in head and neck cancer. However, the small endoscopic
biopsies may have lessened the reliability of the p16INK4a
immunohistochemistry. Another concern was selection bias
introduced by patients from certain hospitals more often being
excluded.
This study did not reveal any higher occurrence of HPV
infection in the tumour location of the upper third of the
oesophagus as hypothesised. Instead, most tumours positive for
HPV DNA were located in the middle third of the oesophagus.
This might merely be an effect of chance, or speculatively this
might be a true finding. The middle part of the oesophagus, the
transition zone, holds no significant contraction amplitude when
measuring peristaltic contractions, [28] and this region is collapsed
in resting state, which might allow virus particles to implant more
easily.
To our knowledge, this is the first study comparing the
association between HPV infection and the development of
squamous cell carcinoma in different locations in the oesophagus
as the primary endpoint. Previous studies show diversity in
frequency of tumours containing HPV DNA. A review article
from 2002 looking at frequency of HPV DNA in oesophageal
tumours showed great diversity of between 0 and 70% of tumours
containing HPV DNA. [11] Different methods were used for
detection of HPV, however when pooling the studies using only
PCR, the incidence of HPV was 15% (308/2020), which is
comparable to the present study (10%). Our results are also
consistent with a previous study from Sweden looking at HPV in
oesophageal squamous cell carcinoma, where 16% of tumours
contained HPV DNA. [14]
Although 90% of the HPV positive tumours harboured high-
risk HPV types (and 5% putative high-risk types), we found no
correlation between the subset of tumours containing HPV DNA
and p16 INK4a expression. The low portion (24%) of overexpres-
Table 2. Characteristics of HPV positive versus HPV negative
participants.
Variable
HPV
negative HPV positive p-value
Number (%) Number (%)
Total 184 (90) 20 (10)
Sex
Men 113 (61) 14 (70) 0.628
Women 71 (39) 6 (30)
Age at diagnosis
(years)
,60 32 (17) 5 (25) 0.426
60–70 71 (39) 5 (25)
.70 81 (44) 10 (50)
Tumor location
Upper third 49 (27) 4 (20) 0.151
Middle third 53 (29) 11 (55)
Lower third 78 (42) 5 (25)
Tumor differentiation
High 10 (5) 2 (9) 0.426
Middle 100 (54) 13 (62)
Low 72 (39) 6 (29)
Total* 113 (87) 17 (13)
p16
Negative 95 (84) 13 (76) 0.488
Positive 18 (16) 4 (24)
*p16 analysis was conducted on 130 (64%) out of 204 patients.
Percentages not adding to 100% are due to missing data.
doi:10.1371/journal.pone.0046538.t002
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sion of p16INK4a in the HPV positive cancer biopsies indicate that
HPV may not be involved in tumour progression in oesophageal
cancer to a large extent. These results are in line with a recent
case-control study of 222 patients with oesophageal squamous cell
carcinoma. [17] Only 3.6% (8/222) of tumours were HPV positive
and only 4 of the 8 HPV positive cases also overexpressed p16
INK4a. [17] However, it is not implausible that the small
endoscopic biopsies lessened the reliability of immunohistochem-
istry.
In conclusion, this population-based study from Sweden found
limited presence of HPV with uncertain oncogenic relevance in
oesophageal squamous cell carcinoma and could not demonstrate
that HPV was more likely associated to proximal than distal
squamous cell carcinomas of the oesophagus.
Novelty and impact statement
The presence of human papillomavirus (HPV) in oesophageal
squamous cell carcinoma was not correlated to the tumour
location within the oesophagus
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